Payment overview · 2025
General Payments
$21,295.37
67 reported records · 13 companies
Healthcare provider profile · identity verified
Ashley Darnell Mcintyre, MD
Allopathic & Osteopathic Physicians|General Practice · MONTGOMERY, AL · NPI 1699747709
Verified facts
What the public records show
CMS Open Payments records show Ashley Darnell Mcintyre, MD received $21,295.37 in general payments during 2025 across 67 reported records.
Novo Nordisk Inc accounted for 77.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Kerendia, Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 156 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Synjardy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 156 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 261 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16,406.56 | 77.0% | 18 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $2,477.30 | 11.6% | 13 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $1,804.44 | 8.5% | 7 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $129.16 | 0.6% | 6 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $101.12 | 0.5% | 4 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $91.98 | 0.4% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $71.56 | 0.3% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $66.31 | 0.3% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $37.20 | 0.2% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $33.59 | 0.2% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $27.95 | 0.1% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $27.72 | 0.1% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $20.48 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $19,092.19 | 16 |
| Food and Beverage | $1,226.83 | 49 |
| Travel and Lodging | $976.35 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $15,396.16 | 16 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $3,755.68 | 17 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $129.16 | 6 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $101.12 | 4 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $91.98 | 5 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $71.56 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $66.31 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $60.08 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $37.20 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $33.59 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $27.95 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $27.72 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $26.06 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $20.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 156 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 57 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 92 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 261 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
87 | 21 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
51 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
56 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
57 | 14 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
156 | 38 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
156 | 38 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
92 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
261 | 46 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 1003 | 294 |
| Atorvastatin Calcium | Atorvastatin Calcium | 875 | 230 |
| Losartan Potassium | Losartan Potassium | 545 | 166 |
| Metformin Hcl | Metformin Hcl | 531 | 152 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 518 | 159 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 468 | 149 |
| Ibuprofen | Ibuprofen | 465 | 128 |
| Hydrochlorothiazide | Hydrochlorothiazide | 440 | 128 |
| Pantoprazole Sodium | Pantoprazole Sodium | 403 | 120 |
| Levothyroxine Sodium | Levothyroxine Sodium | 353 | 94 |
| Simvastatin | Simvastatin | 334 | 84 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 323 | 92 |
| Gabapentin | Gabapentin | 300 | 93 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 288 | 84 |
| Meloxicam | Meloxicam | 288 | 79 |
| Omeprazole | Omeprazole | 274 | 81 |
| Ozempic | Semaglutide | 261 | 46 |
| Carvedilol | Carvedilol | 250 | 75 |
| Hydralazine Hcl | Hydralazine Hcl | 220 | 60 |
| Furosemide | Furosemide | 205 | 63 |
| Spironolactone | Spironolactone | 195 | 55 |
| Methylprednisolone | Methylprednisolone | 191 | 155 |
| Allopurinol | Allopurinol | 175 | 55 |
| Metoprolol Succinate | Metoprolol Succinate | 174 | 48 |
| Fluticasone Propionate | Fluticasone Propionate | 173 | 72 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 172 | 63 |
| Lisinopril | Lisinopril | 168 | 46 |
| Ezetimibe | Ezetimibe | 159 | 50 |
| Glipizide | Glipizide | 159 | 46 |
| Tamsulosin Hcl | Tamsulosin Hcl | 159 | 54 |
| Jardiance | Empagliflozin | 156 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 141 | 45 |
| Montelukast Sodium | Montelukast Sodium | 141 | 52 |
| Potassium Chloride | Potassium Chloride | 138 | 48 |
| Eliquis | Apixaban | 132 | 29 |
| Azithromycin | Azithromycin | 127 | 101 |
| Citalopram Hbr | Citalopram Hydrobromide | 127 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 119 | 39 |
| Tresiba Flextouch U-200 | Insulin Degludec | 108 | 20 |
| Fluconazole | Fluconazole | 106 | 38 |
| Famotidine | Famotidine | 104 | 35 |
| Pioglitazone Hcl | Pioglitazone Hcl | 102 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 100 | 24 |
| Januvia | Sitagliptin Phosphate | 99 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 95 | 21 |
| Mounjaro | Tirzepatide | 92 | 15 |
| Xarelto | Rivaroxaban | 91 | 18 |
| Linzess | Linaclotide | 87 | 21 |
| Meclizine Hcl | Meclizine Hcl | 81 | 28 |
| Trazodone Hcl | Trazodone Hcl | 81 | 21 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 80 | 63 |
| Tizanidine Hcl | Tizanidine Hcl | 75 | 21 |
| Vascepa | Icosapent Ethyl | 75 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 74 | 20 |
| Colchicine | Colchicine | 73 | 20 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 68 | 29 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 67 | 17 |
| Levofloxacin | Levofloxacin | 67 | 58 |
| Clonidine Hcl | Clonidine Hcl | 66 | 21 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 66 | 32 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 66 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 63 | 25 |
| Testosterone Cypionate | Testosterone Cypionate | 58 | 18 |
| Kerendia | Finerenone | 57 | 14 |
| Farxiga | Dapagliflozin Propanediol | 56 | 14 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 56 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 55 | 19 |
| Methocarbamol | Methocarbamol | 55 | 22 |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 55 | 13 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 55 | 12 |
| Labetalol Hcl | Labetalol Hcl | 54 | 15 |
| Sumatriptan Succinate | Sumatriptan Succinate | 53 | 14 |
| Telmisartan | Telmisartan | 53 | 16 |
| Alendronate Sodium | Alendronate Sodium | 52 | suppressed |
| Synthroid | Levothyroxine Sodium | 51 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 50 | 20 |
| Amoxicillin | Amoxicillin | 50 | 36 |
| Ondansetron Odt | Ondansetron | 45 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | 12 |
| Lovastatin | Lovastatin | 44 | 15 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 43 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 43 | 15 |
| Promethazine Hcl | Promethazine Hcl | 43 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 43 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 41 | 12 |
| Metformin Hcl Er | Metformin Hcl | 41 | 15 |
| Glyxambi | Empagliflozin/Linagliptin | 40 | 12 |
| Pregabalin | Pregabalin | 40 | 11 |
| Valacyclovir | Valacyclovir Hcl | 39 | 15 |
| Atenolol | Atenolol | 37 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 37 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 37 | 14 |
| Ramipril | Ramipril | 37 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 37 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 36 | suppressed |
| Metronidazole | Metronidazole | 36 | 30 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 36 | 13 |
| Rybelsus | Semaglutide | 36 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 35 | 15 |
| Glipizide Er | Glipizide | 34 | 14 |
| Estradiol | Estradiol | 33 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 33 | 15 |
| Buspirone Hcl | Buspirone Hcl | 32 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 28 |
| Tradjenta | Linagliptin | 32 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 31 | suppressed |
| Topiramate | Topiramate | 31 | suppressed |
| Memantine Hcl | Memantine Hcl | 29 | 11 |
| Glimepiride | Glimepiride | 28 | suppressed |
| Mirtazapine | Mirtazapine | 28 | suppressed |
| Naproxen | Naproxen | 28 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 28 | suppressed |
| Chlorthalidone | Chlorthalidone | 27 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 27 | 13 |
| Levemir Flexpen | Insulin Detemir | 27 | suppressed |
| Nystatin | Nystatin | 27 | 11 |
| Sertraline Hcl | Sertraline Hcl | 27 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 26 | 13 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 26 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 19 |
| Entresto | Sacubitril/Valsartan | 25 | suppressed |
| Indapamide | Indapamide | 25 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 24 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Alprazolam | Alprazolam | 23 | suppressed |
| Cephalexin | Cephalexin | 23 | 21 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 23 | 20 |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Primidone | Primidone | 22 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 21 | 13 |
| Nebivolol Hcl | Nebivolol Hcl | 21 | suppressed |
| Prednisone | Prednisone | 21 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 18 | 11 |
| Klor-Con 10 | Potassium Chloride | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 16 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Sucralfate | Sucralfate | 16 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 15 | 11 |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Belsomra | Suvorexant | 14 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 14 | suppressed |
| Brilinta | Ticagrelor | 14 | suppressed |
| Insulin Lispro | Insulin Lispro | 14 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 14 | suppressed |
| Methimazole | Methimazole | 14 | suppressed |
| Trulance | Plecanatide | 14 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 13 | suppressed |
| Ibu | Ibuprofen | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Terconazole | Terconazole | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Haloperidol | Haloperidol | 11 | suppressed |
| Indomethacin | Indomethacin | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 11 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $21,295.37 · 67 records | Novo Nordisk Inc | AIRSUPRA, CAPLYTA, INSPIRE, JARDIANCE, KRYSTEXXA, Kerendia, Korlym, MOUNJARO, Ozempic, REXULTI, Rybelsus, UBRELVY, VERQUVO, VOQUEZNA | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error